Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Akshaya Sharon: Qfitlia as a Shift in Treatment Strategy for Hemophilia A and B
Akshaya Sharon/LinkedIn
Apr 1, 2026, 17:47

Akshaya Sharon: Qfitlia as a Shift in Treatment Strategy for Hemophilia A and B

Akshaya Sharon, Pharmacy student at JKK Nattraja College of Pharmacy, shared a post on LinkedIn:

“A major leap in hemophilia care – less frequent dosing, broader applicability.

On March 28, 2025, the U.S. FDA approved Qfitlia (fitusiran) – a novel prophylactic treatment for patients with Hemophilia A and B, with or without factor inhibitors.

This approval stands out not just as another drug launch – but as a shift in treatment strategy.

Unlike traditional therapies that replace missing clotting factors, Qfitlia works differently:

  • It targets antithrombin, indirectly increasing thrombin generation
  • This enhances clot formation without directly supplying FVIII or FIX

Why this matters:

  • Extended dosing interval – administered once every 2 months
  • Effective across both inhibitor and non-inhibitor patients
  • Demonstrated ~70% reduction in annual bleeding rates
  • Moves care closer to precision-guided dosing using companion diagnostics

The integration of the Innovance Antithrombin diagnostic test is especially notable – marking a step toward personalized prophylaxis, where dosing is adjusted based on biological response rather than fixed schedules.

However, innovation comes with caution.

Qfitlia carries serious safety considerations:

  • Risk of thrombotic events
  • Liver toxicity monitoring required
  • Potential gallbladder complications

This approval reflects a broader trend in therapeutics:

  • Moving from replacement therapies – pathway modulation
  • From frequent dosing – long-acting precision care

For clinicians and researchers, this opens new discussions around balancing efficacy with safety, especially in long – term management.

For patients, it offers something equally powerful – convenience with improved outcomes.

A promising step forward in redefining hemophilia management.”

Akshaya Sharon

Stay updated on all scientific updates with Hemostasis Today.

Akshaya Sharon Fitusiran Health Hematology Hemophilia Hemostasis Hemostasis News Hemostasis Today Medicine Qfitlia
NewsFeed